IBD patients persist with newer biologics: Australian study

Medication persistence is highest with non-anti-TNF agents ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared to other biologics, according to an Australian study. The Persistence Australian National IBD Cohort (PANIC) study, published in Alimentary Pharmacology and Therapeutics, compared medication persistence across four biologic agents in 2,499 patients with 8,219 person-years of follow-up. The ...

Already a member?

Login to keep reading.

© 2021 the limbic